FELIWAY® works to help prevent urine spraying and scratching.
Cats don’t want to scratch or spray where they detect the feline facial pheromone.
Also provided are novel pharmaceutical compositions for treating and/ or preventing allergic and inflammatory conditions with cough in humans comprising an effective amount of a non-sedating antihistamine in combination with an expectorant and a pharmaceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel pharmaceutical formulations, which consist essentially of a combination of a non- sedating antihistamine and an expectorant.
Typical allergic and inflammatory conditions of the skin or upper and lower airway passages include seasonal and perennial allergic rhinitis, non- allergic rhinitis, asthma including allergic and non-allergic asthma, sinusitis, colds, dermatitis, especially allergic and atopic dermatitis, and urticaria and symptomatic dermographism as well as retinopathy, and small vessel diseases, associated with diabetes mellitus.
The term "a human age 6- 12 years" as used herein means a male or female pediatric subject of 6 years of age to 12 years of age. Loratadine is a potent tricyclic and antihistaminic drug with a selective antagonist of peripheric Hi receptors activity. 4,659,716, 5,595,997 and 4,804,666 disclose methods of making desloratadine, pharmaceutical compositions containing it and methods for using it to treat various disease states in mammals. DCL is an antagonist of the H- l histamine receptor protein.
The formulations of the invention are useful in the prevention and/ or treatment of allergic and inflammatory conditions of the skin or airway passages with cough.
The formulations are useful for a wide range of patient ages; specific embodiments provided herein include a tablet form for administration to humans 12 years and older, and a pediatric solution for humans aged 6- 12 years.
Likewise, mucolytic expectorants have been known in the art for some time. SUMMARY OF THE INVENTION The present invention provides methods for treating and/ or preventing allergic and inflammatory conditions with related cough in humans in need of such treating and/ or preventing which comprises administering an effective amount of a non- sedating antihistamine and an expectorant.
Preferably, the concentration of ambroxol is in the range of 3.0 mg/ml to 18.0 mg/ml per day to be administered in single or divided doses according to body weight; more preferably about 12.0 mg/ml in single or divided doses, most preferably about 6 mg/ml to be administered according to body weight twice a day.
The dosage amount of ambroxol will preferably range from about 0.5 mg/kg per day to about 2.0 mg/kg per day, more preferably from about 1.0 mg/kg per day to about 2.0 mg/kg per day, most preferably from about 1.0 mg/kg per day to about 1.5 mg/kg per day.
COMPOSITIONS AND METHODS FOR TREATING ALLERGIC AND INFLAMMATORY CONDITIONS WITH COUGH BACKGROUND OF THE INVENTION This invention relates to treating and/ or preventing allergic and inflammatory conditions with related productive and non-productive cough in humans by administering a combination of a non- sedating antihistamine and an expectorant. In particularly preferred embodiments, the amount of loratadine is in the range of about 0.5 mg to about 15.0 mg in single or divided doses.
In preferred embodiments, the antihistamine is loratadine and the expectorant is ambroxol.